Arbutus Biopharma Corporation
ABUSNASDAQHealthcare● Active
$4.24
$-0.02(-0.35%)
Market Cap$836572202
P/E Ratio—
52W High$5.1
52W Low$3.04
Arbutus Biopharma Corporation (ABUS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ABUS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
$0.87
Est. -$0.03 · +3000.0%
Revenue
$0.18B
Est. $0.00B · +23783.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
ABUS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.03 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.03 | $0.87 | +3000.0% | $0.18B | $0.00B | +23783.5% |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$0.04 | -$0.01 | +71.5% | $0.00B | $0.00B | +71.0% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.06 | -$0.04 | +28.6% | $0.00B | $0.00B | -37.1% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.02 | $0.01 | +150.0% | $0.01B | $0.00B | +575.0% |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.09 | -$0.13 | -44.4% | $0.00B | $0.00B | -21.3% |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.08 | -$0.07 | +12.5% | $0.00B | $0.00B | -30.3% |
| — Q4 FY2024 | Nov 6, 2024 | -$0.10 | -$0.10 | +0.0% | $0.00B | $0.00B | -15.3% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
$0.87
EPS Est.
-$0.03
EPS Surpr.
+3000.0%
Revenue
$0.18B
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$0.01
EPS Est.
-$0.04
EPS Surpr.
+71.5%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.06
EPS Surpr.
+28.6%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.02
EPS Surpr.
+150.0%
Revenue
$0.01B
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.09
EPS Surpr.
-44.4%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.08
EPS Surpr.
+12.5%
Revenue
$0.00B
Q4 FY2024
Nov 6, 2024
EPS Actual
-$0.10
EPS Est.
-$0.10
EPS Surpr.
+0.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q2 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q1 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q4 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q3 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +3000.0% | $4.31 | $4.31 | +0.00% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +71.5% | $4.24 | $4.42 | +4.25% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +28.6% | $4.84 | $4.56 | -5.79% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +150.0% | $3.41 | $3.47 | +1.76% |
| ▼ Q2 FY2025 | May 14, 2025 | -44.4% | $3.19 | $3.16 | -0.94% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +12.5% | $3.35 | $3.27 | -2.39% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +0.0% | $3.96 | $3.92 | -1.01% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -10.0% | $3.77 | $3.81 | +1.06% |
Q2 FY2026+0.00%
Report Date
May 13, 2026
EPS Beat/Miss
+3000.0%
Price Before
$4.31
Price After
$4.31
Q1 FY2026+4.25%
Report Date
Mar 23, 2026
EPS Beat/Miss
+71.5%
Price Before
$4.24
Price After
$4.42
Q4 FY2025-5.79%
Report Date
Nov 13, 2025
EPS Beat/Miss
+28.6%
Price Before
$4.84
Price After
$4.56
Q3 FY2025+1.76%
Report Date
Aug 6, 2025
EPS Beat/Miss
+150.0%
Price Before
$3.41
Price After
$3.47
Q2 FY2025-0.94%
Report Date
May 14, 2025
EPS Beat/Miss
-44.4%
Price Before
$3.19
Price After
$3.16
Q1 FY2025-2.39%
Report Date
Mar 27, 2025
EPS Beat/Miss
+12.5%
Price Before
$3.35
Price After
$3.27
Q4 FY2024-1.01%
Report Date
Nov 6, 2024
EPS Beat/Miss
+0.0%
Price Before
$3.96
Price After
$3.92
Q3 FY2024+1.06%
Report Date
Aug 1, 2024
EPS Beat/Miss
-10.0%
Price Before
$3.77
Price After
$3.81
Avg Beat Reaction-0.53%
Avg Miss Reaction+0.06%
Beat Rate6 / 8 quarters
Largest Move-5.79% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ABUS ends December
Arbutus Biopharma Corporation (ABUS) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $0.87 — beating the analyst consensus of $-0.03 by +3000.0%. ABUS has beaten EPS estimates for 4 consecutive quarters. The next ABUS earnings date is expected around September 1, 2026.
Each quarter, investors track ABUS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ABUS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ABUS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ABUS earnings · 5 questionsArbutus Biopharma Corporation's next earnings report is expected around September 1, 2026. ABUS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ABUS historically reports after market close (AMC).
ABUS earnings datewhen is ABUS earningsABUS next earnings datewhen does ABUS report earningsABUS earnings calendar
▸ Source: FMP · Arbutus Biopharma Corporation SEC filings · US GAAP · Arbutus Biopharma Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026